Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials

被引:105
作者
Kakkos, S. K. [1 ]
Kirkilesis, G. I. [1 ]
Tsolakis, I. A. [1 ]
机构
[1] Univ Hosp Patras, Dept Vasc Surg, Patras 26504, Greece
关键词
Venous thromboembolism; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; VITAMIN-K ANTAGONISTS; ATRIAL-FIBRILLATION; ANTITHROMBOTIC AGENT; COST-EFFECTIVENESS; IN-VITRO; WARFARIN; POTENT; ENOXAPARIN; INHIBITOR; DISCOVERY;
D O I
10.1016/j.ejvs.2014.05.001
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives: The aim was to perform a review of the efficacy and safety of new oral anticoagulants (NOAs) in the management of venous thromboembolism (VTE). Methods: This was a systematic review and meta-analysis. On March 26, 2014, Medline, Embase, and the Cochrane trial register were searched for randomized controlled trials (RCTs) comparing the NOAs dabigatran, rivaroxaban, apixaban, and edoxaban with vitamin K antagonists (VKAs) in VTE treatment and secondary prevention. Two investigators assessed the methodological quality of the RCTs. The main study outcomes (efficacy, safety and net clinical benefit) were expressed as risk ratios (RR) with 95% confidence interval (Cl). Results: Ten RCTs, mostly with low risk of bias, with nearly 38,000 patients, were identified. In six trials of treatment, NOAs were equally effective as VKAs in preventing recurrent symptomatic VTE (RR 0.89, 95% Cl 0.75-1.05), but major bleeding occurred less often (1.08% vs. 1.73% for VKAs, RR 0.63, 95% Cl 0.51-0.77), leading net clinical benefit to favor NOAs (RR 0.79, 95% Cl 0.70-0.90). Fatal bleeding occurred less often with NOAs (0.09% vs. 0.18% for VKAs), a difference that approached statistical significance (RR 0.51, 95% Cl 0.26-1.01). In three secondary prevention trials, NOAs reduced VTE recurrence rates to 1.32% (vs. 7.24% with placebo, RR 0.17,95% Cl 0.12-0.24) and fatal pulmonary embolism (PE) (including unexplained deaths) to 0.1% (vs. 0.29% for placebo, RR 0.37, 95% Cl 0.10-1.38) at the expense of clinically relevant non-major bleeding (4.3% vs. 1.8% for placebo, RR 2.32, 95% CI 1.65-3.35), but not major bleeding. All-cause mortality rate was reduced to 0.41% with NOAs (vs. 0.86% with placebo, RR 0.38, 95% Cl 0.18-0.79). Net clinical benefit favored NOAs (RR 0.21, 95% Cl 0.15-0.29), and NNT was 18. Conclusions: Compared to VKAs, NOAs are not only effective in treating VTE but also safer in terms of bleeding, thereby conferring clinical benefit. Their safety and efficacy was confirmed further in secondary prevention trials. (C) 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:565 / 575
页数:11
相关论文
共 34 条
[1]   Oral Apixaban for the Treatment of Acute Venous Thromboembolism [J].
Agnelli, Giancarlo ;
Buller, Harry R. ;
Cohen, Alexander ;
Curto, Madelyn ;
Gallus, Alexander S. ;
Johnson, Margot ;
Masiukiewicz, Urszula ;
Pak, Raphael ;
Thompson, John ;
Raskob, Gary E. ;
Weitz, Jeffrey I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (09) :799-808
[2]   Apixaban for Extended Treatment of Venous Thromboembolism [J].
Agnelli, Giancarlo ;
Buller, Harry R. ;
Cohen, Alexander ;
Curto, Madelyn ;
Gallus, Alexander S. ;
Johnson, Margot ;
Porcari, Anthony ;
Raskob, Gary E. ;
Weitz, Jeffrey I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (08) :699-708
[3]   Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study [J].
Baglin, T ;
Luddington, R ;
Brown, K ;
Baglin, C .
LANCET, 2003, 362 (9383) :523-526
[4]   Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].
Bauersachs, Rupert ;
Berkowitz, Scott D. ;
Brenner, Benjamin ;
Buller, Harry R. ;
Decousus, Herve ;
Gallus, Alex S. ;
Lensing, Anthonie W. ;
Misselwitz, Frank ;
Prins, Martin H. ;
Raskob, Gary E. ;
Segers, Annelise ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Bounameaux, Henri ;
Cohen, Alexander ;
Davidson, Bruce L. ;
Piovella, Franco ;
Schellong, Sebastian .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510
[5]   Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism [J].
Bueller, Harry R. ;
Decousus, Herve ;
Grosso, Michael A. ;
Mercuri, Michele ;
Middeldorp, Saskia ;
Prins, Martin H. ;
Raskob, Gary E. ;
Schellong, Sebastian M. ;
Schwocho, Lee ;
Segers, Annelise ;
Shi, Minggao ;
Verhamme, Peter ;
Wells, Phil .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (15) :1406-1415
[6]  
Buller HR, 2007, NEW ENGL J MED, V357, P1094
[7]   Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism [J].
Buller, Harry R. ;
Prins, Martin H. ;
Lensing, Anthonie W. A. ;
Decousus, Herve ;
Jacobson, Barry F. ;
Minar, Erich ;
Chlumsky, Jaromir ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Cohen, Alexander ;
Berkowitz, Scott D. ;
Bounameaux, Henri ;
Davidson, Bruce L. ;
Misselwitz, Frank ;
Gallus, Alex S. ;
Raskob, Gary E. ;
Schellong, Sebastian ;
Segers, Annelise .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (14) :1287-1297
[8]   Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation A Systematic Review and Meta-Analysis of the Literature [J].
Dentali, Francesco ;
Riva, Nicoletta ;
Crowther, Mark ;
Turpie, Alexander G. G. ;
Lip, Gregory Y. H. ;
Ageno, Walter .
CIRCULATION, 2012, 126 (20) :2381-+
[9]   Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials [J].
Fox, Benjamin D. ;
Kahn, Susan R. ;
Langleben, David ;
Eisenberg, Mark J. ;
Shimony, Avi .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
[10]   DU-176b, a potent and orally active factor Xa inhibitor:: in vitro and in vivo pharmacological profiles [J].
Furugohri, T. ;
Isobe, K. ;
Honda, Y. ;
Kamisato-Matsumoto, C. ;
Sugiyama, N. ;
Nagahara, T. ;
Morishima, Y. ;
Shibano, T. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) :1542-1549